Metabolism in Pulmonary Hypertension

Area of Science:

• Cardiovascular Research
• Metabolic Diseases
• Mitochondrial Biology

Background:

• Pulmonary arterial hypertension (PAH) involves abnormal pulmonary hemodynamics and vascular growth.
• Metabolic and bioenergetic alterations are recognized as hallmarks of PAH across various affected tissues and models.
• Mitochondria play a central role in mediating metabolic pathways crucial for cellular function.

Purpose of the Study:

• To review metabolic pathway alterations linked to the vascular pathology of PAH.
• To explore the impact of mitochondrial and nuclear mutations on PAH metabolism.
• To highlight the potential of metabolic understanding for developing novel PAH therapeutics.

Main Methods:

• Literature review of metabolic alterations in PAH.
• Analysis of metabolic pathways including glycolysis, fatty acid oxidation, and glutaminolysis.
• Examination of the role of mitochondria and cellular redox environment in PAH.

Main Results:

• PAH is associated with abnormalities in glucose oxidation, fatty acid oxidation, glutaminolysis, arginine metabolism, and one-carbon metabolism.
• The tricarboxylic acid cycle and cellular redox balance are significantly affected in PAH.
• PAH-associated nuclear and mitochondrial mutations impact metabolic pathways.

Conclusions:

• Metabolic dysfunction is integral to the pathogenesis of pulmonary arterial hypertension.
• Targeting metabolic pathways, particularly mitochondrial function, offers promising therapeutic avenues for PAH treatment.
• Further research into PAH's metabolic underpinnings is essential for advancing patient care.